Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Endocrinology | Internal Medicine | Pathology | Conference News

Back to Journal Articles

AHA/HBP: CRP Linked to BP, Metabolic Syndrome

Last Updated: September 25, 2009.

 

Animal study suggests that CRP is associated with a wide range of adverse metabolic changes

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
C-reactive protein is not just a secondary marker of inflammatory disease but may be directly associated with hypertension and the metabolic syndrome, according to research presented this week at the American Heart Association's 63rd High Blood Pressure Research Conference, held from Sept. 23 to 26 in Chicago.

FRIDAY, Sept. 25 (HealthDay News) -- C-reactive protein (CRP) is not just a secondary marker of inflammatory disease but may be directly associated with hypertension and the metabolic syndrome, according to research presented this week at the American Heart Association's 63rd High Blood Pressure Research Conference, held from Sept. 23 to 26 in Chicago.

Michal Pravenec, M.D., of the Czech Academy of Sciences in Videnska, and colleagues studied spontaneously hypertensive rats with or without transgenically expressed human CRP in the liver under control of the apoE promoter.

Compared to control rats, the researchers found that treated rats showed hyperinsulinemia despite similar serum glucose levels, resistance to insulin stimulated non-oxidative glucose metabolism in skeletal muscle, elevated triglycerides, reduced serum adiponectin, and microalbuminuria. They also found evidence that treated rats had increased oxidative tissue damage.

"In addition, the results indicate that humanized CRP transgenic spontaneously hypertensive rats may provide a valuable model for 1) investigating mechanisms whereby human CRP enhances the risk for hypertension, diabetes, and target organ damage and 2) testing the therapeutic effects of new CRP inhibitors being developed for the prevention and treatment of common forms of cardiovascular and metabolic disease," the authors conclude.

More Information

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: FDA Warns Prescribers About Tamiflu Dosing Errors Next: Neck Index Found Adequate in Test-Retest Reliability

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.